ERAP2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL645270	0.59	12/20
SCHEMBL644843	0.57	10/20
SCHEMBL930562	0.57	8/20
SCHEMBL930564	0.57	8/20
Rebamipide (SCHEMBL296716)	0.48	8/20
SCHEMBL296717	0.42	7/20
Tryptophan (SCHEMBL294283)	0.42	6/20
SCHEMBL771670	0.40	6/20
SCHEMBL774189	0.40	6/20
SCHEMBL621015	0.55	5/20
SCHEMBL903409	0.54	5/20
SCHEMBL1109109	0.44	5/20
Rebamipide (SCHEMBL297016)	0.44	5/20
SCHEMBL85021	0.57	4/20
SCHEMBL607885	0.56	4/20
SCHEMBL607886	0.56	4/20
SCHEMBL461810	0.54	4/20
SCHEMBL542066	0.53	4/20
SCHEMBL676260	0.53	4/20
Phosphoramidon (SCHEMBL40933)	0.53	4/20

Clinical trials — most relevant to ERAP2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phenylbutyrate in Proteinuric Nephropathies	PHASE2/PHASE3	COMPLETED
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy	PHASE2	COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity	PHASE2	RECRUITING
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients	PHASE1	UNKNOWN
PBA Use for Treatment of ATF6-/- Patients	EARLY_PHASE1	SUSPENDED
Factors Involved in Asthma and Airway Inflammation	nan	COMPLETED
Purinergic Signaling and the Postmenopausal Heart	nan	RECRUITING
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study	nan	COMPLETED
Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).	nan	COMPLETED
Screening of Lysosomal Storage Disorders Diseases in Minority Groups	nan	UNKNOWN
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease	nan	UNKNOWN
Quantification of GADD34 Expression in RA	nan	COMPLETED
Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management	nan	UNKNOWN
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)	nan	COMPLETED
Fatty Acids Lipidome and Oxidative Stress in Liver Transplantation	nan	UNKNOWN
Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study	nan	RECRUITING
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
Genetic Variants and Regulation of Specialized Pro-resolving Mediator	nan	RECRUITING
Tamoxifen Pharmacogenetics in Asian Breast Cancer Women	nan	UNKNOWN
Pharmacogenetic Determinants Of Treatment Response In Children	nan	RECRUITING
Genetic Studies of Lysosomal Storage Disorders	nan	ENROLLING_BY_INVITATION
Identifying New Therapeutic Targets for Lupus Treatment	nan	COMPLETED
Study to Evaluate EnteroTracker® as a Sampling Method to Screen for Barrett's Esophagus/Esophageal Cancer	nan	ENROLLING_BY_INVITATION
The Influence of Genetic Variations in ELAPOR1 or ELAPOR2 on Insulin Secretion and Glucose Regulation in Humans	nan	UNKNOWN
Chromosome 5Q Gene Variants and Asthma-Related Traits	nan	COMPLETED
Family Blood Pressure Program - GenNet Network	nan	COMPLETED
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis	nan	COMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ERAP2 binder may also engage these)

Protein	Name	Similarity
Q9JJ22	—	1.000	Q9JJ22 →
Q5RFP3	—	1.000	Q5RFP3 →
A6QPT7	—	1.000	A6QPT7 →
Q8C129	—	1.000	Q8C129 →
LNPEP	Leucyl-cystinyl aminopeptidase	1.000	landscape →
P97629	—	0.999	P97629 →
Q9EQH2	—	0.997	Q9EQH2 →
ENPEP	Glutamyl aminopeptidase	0.997	landscape →
P97449	—	0.996	P97449 →
ERAP1	Endoplasmic reticulum aminopeptidase 1	0.996	landscape →
D3UW23	—	0.996	D3UW23 →
A5HUI5	—	0.995	A5HUI5 →
P79171	—	0.994	P79171 →
P15145	—	0.994	P15145 →
Q6Q4G3	—	0.992	Q6Q4G3 →
ANPEP	Aminopeptidase N	0.991	landscape →
P15541	—	0.991	P15541 →
Q32LQ0	—	0.991	Q32LQ0 →
Q6K4E7	—	0.991	Q6K4E7 →
M3XFH7	—	0.991	M3XFH7 →
Q95334	—	0.991	Q95334 →
Q9Z218	—	0.989	Q9Z218 →
P28843	—	0.989	P28843 →
Q0J5V5	—	0.989	Q0J5V5 →
NPEPPS	Puromycin-sensitive aminopeptidase	0.989	landscape →
P32454	—	0.989	P32454 →
MGAM2	Probable maltase-glucoamylase 2 (Maltase-gluc	0.989	landscape →
Q6Z6L4	—	0.989	Q6Z6L4 →
P79143	—	0.989	P79143 →
Q5IS50	—	0.988	Q5IS50 →